568P First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results

D Planchard, A Poltoratskiy + Show 17 more

https://doi.org/10.1016/j.annonc.2023.10.646

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Publication Date: Nov 1, 2023

Affiliation: Asan Medical Center, Seoul National University Hospital, Japanese Foundation For Cancer Research, Saitama Medical University, Taipei Medical University, Prince Charles Hospital, Taichung Veterans General Hospital, National Taiwan University, St George Hospital, Austin Health, Kanazawa University Hospital, Dana-Farber Cancer Institute

#Safety Run-in #EGFR-mutated Advanced NSCLC + Show 5 more

Abstract
Full-Text PDF
Similar Papers

Abstract

568P First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results

Full Text

Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of oncology : official journal of the European Society for Medical Oncology

Paper Title

Journal

Date

Author

View more papers

Translate this paper in your preferred language
Listen to the abstract of this paper

Save
Share
Export